Founder led companies can be especially interesting when inflation, rates, energy costs, and growth momentum are all pulling markets in different directions. With central banks weighing inflation data, bond markets reacting to policy expectations, and sectors responding differently to trade, energy, and housing trends, many investors are looking for leaders who are deeply aligned with long term outcomes. This article focuses on that theme by using a founder led screener built around personal commitment and accountability, and it highlights 3 stocks from the list that many investors are currently watching closely.

On Holding (ONON)

Overview: On Holding is a Zurich based sportswear company that designs and sells performance footwear, apparel, and accessories under the On brand for activities like running, outdoor, tennis, and everyday wear, reaching athletes and lifestyle consumers through both wholesale partners and its own stores and e-commerce channels across Europe, the US, Asia-Pacific, and other regions.

Operations: On Holding generates essentially all of its CHF 3.1b in revenue from athletic footwear, with Asia-Pacific contributing CHF 564.5m and the remainder captured in a segment adjustment that reflects other regions.

Market Cap: CHF 12.4b

Investors looking at founder led companies may find On Holding interesting because its direct to consumer and e-commerce focus is linked to higher margins, stronger control over pricing, and a global community of runners and lifestyle buyers. Analyst forecasts in the market commentary also highlight expectations for revenue and earnings growth that are connected to new product franchises and expansion into apparel and tennis. At the same time, the premium pricing model, heavy marketing spend, and rapid Asia-Pacific rollout introduce risks if consumer trends or regional demand shift, particularly given a P/E that is described as sitting above the broader luxury peer group in market discussions. The balance between that valuation and the brand’s long term strategic ambitions is a key consideration for understanding On Holding.

On Holding’s premium P/E and growth story often get all the attention, but the bigger question is how that pricing compares with the company’s long term plan. Get the full picture with the DCF valuation analysis for On Holding

China Medical System Holdings (SEHK:867)

Overview: China Medical System Holdings is a Hong Kong headquartered pharmaceutical company that manufactures, markets, and promotes a wide range of cardio, gastroenterology, dermatology, and eye care treatments across mainland China, working with both patented drugs and licensed products from partners.

Operations: China Medical System Holdings generates about CN¥7.2b from its Integrated Business and CN¥1.1b from its Skin Health Business, with virtually all of its roughly CN¥8.2b in revenue coming from the PRC.

Market Cap: HK$30.5b

China Medical System Holdings stands out in the founder led group because it combines an established drug portfolio in cardiovascular, digestive, and skin health with a growing pipeline, such as recently approved Silevimig Injection for rabies prevention and MG-K10 for allergic conditions under review. Analysts expect earnings and revenue growth ahead of the wider Hong Kong market, and the stock is described as trading well below some fair value estimates, even though the current P/E sits in line with peers. Still, funding that leans on external borrowing and pressure on profit margins mean you need to weigh balance sheet risk against future product launches and the potential of its expanding specialty franchise.

China Medical System Holdings is being discussed as a potential growth and valuation reset story. The key issue is how its drug pipeline, borrowing, and margin pressure fit together. Get the fuller context in the analysis report for China Medical System Holdings

GH Research (GHRS)

Overview: GH Research is a Dublin based clinical stage biopharmaceutical company developing mebufotenin based treatments for severe mood disorders, including treatment resistant depression, bipolar II disorder, and postpartum depression, using inhaled and intravenous drug candidates currently in early and mid stage trials in the US.

Market Cap: US$1.8b

GH Research is attracting attention because it sits at the intersection of two themes: next generation depression treatments and a more open regulatory stance on supervised psychedelics. Recent FDA guidance and a planned public hearing may help reduce one of the key uncertainties for this kind of stock. Early data in postpartum depression, with symptom reductions and clean safety signals, gives the story clinical substance, even though the company is still reporting losses and is not expected to generate revenue for several years. A rich P/B multiple, ongoing cash burn, reliance on external borrowing, and follow on equity offerings mean dilution and funding risk are prominent considerations. This makes the emerging trial readouts and changing sentiment around short acting psychedelics important to watch.

GH Research’s accelerating depression pipeline and the changing FDA tone on psychedelics could be masking a very different risk reward profile than many assume, so it is worth reviewing the analyst forecasts for GH Research

The three founder led companies in this article are just a starting point, and the full founder led screener on Simply Wall St surfaced 1,452 more businesses with leadership teams whose own legacies are closely tied to their stock outcomes, all organized in the Founder-Led Companies screener. Use the Simply Wall St platform to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction founder led opportunities.

Take Control of Your Investment Journey

If GH Research or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Picks?

Some of the strongest breakout stories can fly under the radar for now, then move fast once momentum builds. Explore fresh ideas before the crowd catches on and consider acting sooner rather than later.

• Spot potential cash rich opportunities that others overlook by scanning our curated list of solid balance sheet and fundamentals (47 results) built to surface businesses where financial strength still matters.
• Explore upside in fast evolving themes by reviewing the hand picked 31 AI small caps that focus on companies building real products around artificial intelligence.
• Position for income while prices are still dropping or drifting by checking out a targeted group of 8 dividend fortresses that emphasise durability alongside yield.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.